Effects of lovastatin and pentoxyphyllin in nonalcoholic steatohepatitis.
Today, there is no ideal treatment for nonalcoholic steatohepatitis. The present study intended to make a multicentric prospective study about the efficiency of lovastatin and pentoxyphyllin administered in patients with nonalcoholic steatohepatitis. 87 patients were included in the present study. The patients diagnosed with nonalcoholic steatohepatitis and dislypidemia were treated for 4 months with lovastatin 10 mg/day and those without dislypidemia with pentoxyphyllin, 400 mg x 3/day. The patients were evaluated clinically and biochemically monthly. Regarding the lovastatin-treated group, transaminases significantly decreased (p < 0.05), after the first and second month, as well as cholesterolemia (p < 0.001), and the APRI score after 2 months (p = 0.03). In the pentoxyphyllin-treated group, transaminases significantly decreased after 1 month (p < 0.05), and the Forns index after 2 months (p < 0.05). Both drugs significantly decreased the transaminases. Lovastatin reduced the cholesterolemia in the dislipidemic patients. The decrease of the APRI score suggests that both medicines have benefic effects on the hepatic histology, too.